Cardiotoxicity and cancer therapy.
1Department of Clinical Biochemistry (Vascular Prevention Clinic), University College London Medical School, London, United Kingdom.
I
I
Vasiliadis
G
G
Kolovou
D P
DP
Mikhailidis
D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D002319:Cardiovascular System / Q000187:drug effects* / Q000528:radiation effects*; D016893:Carotid Stenosis / Q000209:etiology; D003327:Coronary Disease / Q000209:etiology; D005355:Fibrosis / Q000209:etiology; D006321:Heart / Q000187:drug effects / Q000528:radiation effects; D006329:Heart Conduction System / Q000187:drug effects / Q000528:radiation effects; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D009206:Myocardium / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D017410:Practice Guidelines as Topic; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D013923:Thromboembolism / Q000139:chemically induced; D013997:Time Factors; D059289:Vascular Stiffness / Q000528:radiation effects
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal